LumentumLumentum Holdings Inc. · LITE
September-quarter revenue of $1.26B (+136.5%) and a 28.0% operating margin are strong, but the fixed 4.5-share exchange ties the stock to Marvell's share price and leaves uncertainty until the deal closes.
Marvell's deal is a fixed 4.5-share exchange, so the Nov 9 close of $596.16 sits 14.3% below the $695.70 implied value; September-quarter revenue grew 136.5%, but the merger timeline is the biggest swing factor. Forward P/E of 19.6x is close to the peer median of 18.2x with expected EPS up 60.9%, and the average analyst price target of $1,066.59 is 78.9% above the close.
Marvell implied value $695.70, close 14.3% below
After Marvell agreed to buy Lumentum on Nov 2, the stock plunged 18.7% by Nov 5 and rebounded 10.7% on Nov 9, but it still trades 14.3% below the $695.70 value implied by the fixed 4.5-share ratio.
What happened
Marvell and Lumentum jointly announced the acquisition on Nov 2, and AI infrastructure stocks then sold off, with reports putting Marvell down 36% and Lumentum down 31% since the announcement. Lumentum fell to $509.70 on Nov 5, closing below half of its Oct 9 high of $1,143.
What it means
Lumentum holders get 4.5 Marvell shares per share, and would own about 33% (company announcement, fully diluted) of the combined company against Marvell's roughly 67%. Because the ratio is fixed, a lower Marvell price cuts the value received: the implied value fell from about $1,132 at announcement to $695.70 on Nov 9, down 38.5%.
How the stock reacted
It bounced 5.7% on Nov 6 and 10.7% on Nov 9 but remains 14.3% below the implied value, and reports of an 11–12% intraday gain on Nov 10 came after the close and are not yet in the price. Next checks are Marvell's share price and the shareholder vote and regulatory schedule.
Research team debate
Of six issues, earnings, valuation, cash and optical demand rule Bull while the Marvell deal and price target cuts rule Bear, so the weighted 4-to-3 tally makes the overall call HOLD.
The overall call is HOLD. Earnings and valuation favor the Bull side, but the 14.3% discount to the Marvell implied value and the target cuts favor the Bear side, so the call reopens when deal terms change or Marvell's stock stabilizes.
- Bull case — September-quarter revenue +136.5% and a 28.0% operating margin, with expected EPS up 60.9% for a PEG of 0.39 on the 23.9x June-2027 P/E.
- Bear case — the 4.5-share structure leaves the implied value 38.5% below announcement, and there were six target cuts in eight days.
- Hold — no issue was held. The call reopens when Marvell's stock rises or deal terms are adjusted.
1aDebate by Issue · 6
The discount can be an opportunity. The $596.16 close on Nov 9 is 14.3% below the $695.70 implied by Marvell's $154.60 × 4.5 shares, and if the merger closes as planned the gap has room to narrow. Lumentum holders would own about 33% of the combined company per the companies' announcement (fully diluted basis).
The discount is the market pricing in risk. The implied value fell from about $1,132 at announcement to $695.70 as Marvell dropped to $154.60, a 38.5% decline, and Lumentum is 34.8% below its pre-deal $913.95 (Oct 28). Closing is targeted for the first half of 2028 with shareholder votes and regulatory review pending, so the stock stays tied to Marvell until then.
If Marvell rebounds, the implied value rises with it. When optical stocks bounce, as Lumentum did with a 10.7% gain on Nov 9, the discount can narrow.
The issue is whether the terms favor shareholders: the implied value is 38.5% below announcement with nearly two years to closing, leaving price risk with holders, so the ruling goes to Bear.[S1·S7·S6]
Results beat expectations. September-quarter revenue was $1.26B, up 136.5% year over year, with a 28.0% operating margin, and non-GAAP EPS was $4.57. December-quarter revenue guidance of $1.58B–$1.63B is 25–29% above the prior quarter.
Strong results did not protect the stock. It fell 18.6% on the Nov 2 release (15.34M shares, 2.4x the 20-day average) and another 18.7% on Nov 5 to close at $509.70. With value tied to Marvell's share price, Lumentum's own results carry less weight.
The issue is whether results support value: revenue, margin and next-quarter guidance are all strong, and the decline came from deal terms, so the results themselves rule Bull.[S2·S3·S1]
Targets are still high after the cuts. The average of 25 analysts, $1,066.59, is 78.9% above the close, with 19 Buy, 6 Hold and 0 Sell. Bernstein raised its target from $635 to $700 on Nov 10, a sign the one-way cutting may be ending.
The direction is mostly down. B. Riley (1,142 → 770), TD Cowen (820 → 685), Susquehanna (1,100 → 950) and Rosenblatt (1,300 → 900) cut on Nov 3, followed by Bernstein 900 → 635 on Nov 9 and UBS 960 → 686 (Neutral kept) on Nov 10. That is six cuts against one raise in eight days, and B. Riley also cut its rating to Hold.
Target changes are judged by recent direction: six cuts against one raise in eight days, with one firm also cutting its rating, so the ruling goes to Bear.[S4·S10]
Relative to growth the burden is small. Fiscal-year expected EPS rises from $24.94 (June 2027) to $40.13 (June 2028), up 60.9%, so the PEG at 23.9x June-2027 P/E is 0.39 (Forward P/E of 19.6x is a next-12-month figure, so the PEG is recomputed on the same fiscal-year EPS). That is only 1.4 turns above the peer Forward P/E median of 18.2x.
Relative to sales the stock is still expensive. P/S of 14.4x is 2.3 times the peer median of 6.3x, and only Marvell at 14.7x is higher among peers. If sales growth slows the multiple can compress first, and TTM P/E is not computable because of the June-quarter one-time loss.
Valuation is judged against growth: profit growth of 60.9% gives a PEG of 0.39 and Forward P/E sits 1.4 turns from the peer median, so the ruling goes to Bull. The P/S burden is tolerable while growth continues.[S4·S8]
The balance sheet actually got stronger. Total debt fell 56.4% from $3.28B a year ago to $1.43B, and cash and short-term investments of $1.98B exceed debt by $0.55B. Capex funds InP laser expansion, and free cash flow has been positive for four straight quarters.
Cash is draining quickly. Quarterly free cash flow was $37.9M, down 80.7% from $200M the prior quarter. Capex of $230M took 86% of operating cash flow of $270M, and cash fell from $2.74B at end-June to $1.98B.
The cash decline is large but net cash remains and debt has more than halved, so financial risk is limited and the ruling goes to Bull.[S2]
Demand has not rolled over. AAOI rose 7% on Nov 9 after Q3 earnings, Fabrinet posted a record quarter, and Lumentum guides December-quarter revenue up 25–29%. Reports on Nov 10 had Coherent up 13–18% and Lumentum up 11–12% intraday (after the Nov 9 close, not in the price).
Stocks fell first despite good results. Reports say Fabrinet dropped 33% in a month despite a record quarter and Astera Labs fell 26% in a week on strong earnings, per TIKR headlines (Nov 8 and Nov 10). Lumentum is still 47.8% below its Oct 9 high of $1,143 as of Nov 9, so a rebound could fade within days.
Demand shows up in results and guidance, while the price drop mixes an AI-expectation reset with the Marvell deal, so the demand-side evidence is firmer and the ruling goes to Bull.[S3·S10]
1bScenarios
LightView does not issue its own target price. The high, average and low of external target prices are used as price references for scenarios[S4]
High target of $1,425 · assumes Marvell's stock recovers and December-quarter revenue beats the top of guidance
Average target of $1,066.59 · assumes the merger proceeds on terms and growth meets guidance
Low target of $635 · assumes Marvell falls further or regulatory review drags
1cConditions That Change the Verdict
The verdict is based only on the data in this report and is not a recommendation to buy or sell.
Investment Summary
September-quarter revenue was $1.26B, up 136.5%, with operating income of $0.35B (28.0% margin), and the $596.16 close is 47.8% below the 52-week high of $1,143.
High$1143.00
2aKey Data
Revenue and margin growth and the December-quarter guide are positives; the stock's tie to a fixed exchange ratio, price target cuts and lower free cash flow are the burdens.
2bKey Metrics
Financials are for Q3 2026 (ended Sep 30, company fiscal Q1 2027). The Q2 2026 net loss of −$7.16B includes a $7.76B loss on debt extinguishment (company earnings release, excluded from non-GAAP), and subtracting total debt of $1.43B from cash and short-term investments of $1.98B at Sep 30 gives net cash of $0.55B.
Business & Competitive Advantage
Lasers and optical chips and data center optical parts are the core, and AI data center demand creates most of the growth.
3aBusiness Structure
Expanding indium phosphide (InP) chip capacity to raise supply
Adding capacity as customer demand exceeds supply
Company is pushing to scale the new product
Growth is lower than the AI segment
- Growth driver · Demand for lasers used in AI data centers is driving growth
- Acquisition · On Nov 2, Marvell agreed to acquire Lumentum in an all-stock deal at 4.5 Marvell shares per Lumentum share (needs both shareholder votes and regulatory review; targeted to close in the first half of 2028)
- Outlook · The company guided December-quarter revenue to $1.58B–$1.63B, pointing to continued growth
- Vision · Combine Marvell's chips with Lumentum's optics to expand the AI data center connectivity market
3bCompetitive Advantage (Moat) Assessment
Six sources rated Strong·Medium·Weak
Revenue grew 136.5% in a year with a 28.0% operating margin.
Heavy reliance on AI data center customers means results swing with their capex pace.
TTM revenue of $3.74B is still mid-sized, and quarterly capex runs $230M.
Cash and short-term investments of $1.98B exceed total debt of $1.43B.
Tight supply is lifting margins, but rival Coherent is also adding capacity.
The merger faces regulatory review, and US AI investment policy is also a swing factor.
InP laser technology is strong, but independent strategy is limited until the deal is settled
Earnings & Financials
Quarterly revenue grew from $0.53B in Q3 2025 to $1.26B, and the June-quarter net loss of −$7.16B includes a $7.76B debt extinguishment loss.
4aRevenue & Earnings
| Q3 2025 | Q4 | Q1 2026 | Q2 | Q3 | |
|---|---|---|---|---|---|
| Revenue | 534M | 666M | 808M | 1B | 1.3B |
| Operating Income | 15M | 64M | 176M | 282M | 353M |
| Net Income | 4M | 78M | 144M | −7.2B | 360M |
| Operating Margin | 2.8% | 9.6% | 21.7% | 28.0% | 28.0% |
Operating margin rose 2.8% → 9.6% → 21.7% → 28.0% → 28.0%, and the Q2 net loss of −$7.16B includes a $7.76B loss on debt extinguishment per the company's earnings release, an item the company excludes from non-GAAP results.
4bCash Flow
| Annual (FY ends June) | 23.06 | 24.06 | 25.06 | 26.06 |
|---|---|---|---|---|
| Operating Cash Flow | 180M | 25M | 126M | 751M |
| Capex | 129M | 137M | 231M | 451M |
| Free Cash Flow | +51M | −112M | −105M | +300M |
4cFinancial Structure
| Item | Now | Jun 2026 | Change |
|---|---|---|---|
| Cash and short-term investments (9/30) | $1.98B | $2.74B | −27.7% |
| Total debt (9/30) | $1.43B | $1.67B | −14.4% |
| Equity (9/30) | $4.57B | $4.64B | −1.5% |
| Shares outstanding (9/30) | 90.58M | 88.60M | +2.2% |
4dProfitability Metrics
| Metric | Q3 | Year ago | Calculation |
|---|---|---|---|
| Operating margin | 28.0% | 2.8% | Operating income ÷ revenue |
| Net margin | 28.5% | 0.8% | Net income ÷ revenue |
| Operating cash flow margin | 21.2% | 108.5% | Operating cash flow ÷ revenue |
| Free cash flow margin | 3.0% | −34.3% | (Operating cash flow − capex) ÷ revenue |
Valuation
Forward P/E of 19.6x is close to the peer median of 18.2x with expected EPS up 60.9%, and P/S of 14.4x is 2.3 times the peer median of 6.3x.
5aP/S trend
Trailing diluted EPS is −$78.72 right after the turn to profit, so TTM P/E is not computable and P/S is used instead. Forward 19.6x uses next-12-month expected EPS of $30.44, and fiscal-year expected EPS rises from $24.94 to $40.13, up 60.9%, so the PEG is the June-2027 P/E of 23.9x ÷ 60.9% expected EPS growth = 0.39.
The $596.16 close on Nov 9 is 14.4x P/S on trailing four-quarter revenue and 19.6x next-12-month expected EPS of $30.44. TTM P/E is meaningless because of the June-quarter one-time loss, so Forward 19.6x against the peer median of 18.2x is closer to earnings power.
5bPrice Range · 52-Week vs. External Targets
52-week range is intraday (low 25.11.14 · high 10/9) · External price targets: Yahoo Finance, 25 analysts (Buy 19·Hold 6·Sell 0)[S4]
5cPeer Multiples Comparison
| Company | PER (TTM) | Forward PER | P/S | Market Cap |
|---|---|---|---|---|
| Lumentum LITE | Loss | 19.6x | 14.4x | About $54.06B |
| Coherent COHR | 46.7x | 18.2x | 5.6x | About $44.35B |
| Ciena CIEN | 60.1x | 26.1x | 6.3x | About $38.22B |
| Applied Optoelectronics AAOI | Loss | 15.4x | 6.3x | About $4.68B |
| Fabrinet FN | 27.6x | 17.2x | 2.6x | About $13.11B |
| Marvell MRVL | 51.0x | 23.3x | 14.7x | About $138.92B |
Nov 9 close · peer median TTM 48.9x, Forward 18.2x, P/S 6.3x (five peers, excluding Lumentum) · Yahoo Finance values[S8] · Peers are five optical and networking companies in the same currency (USD) with Yahoo Finance values
Chart & Options
The $596.16 close is below the 20-, 60-, 120- and 200-day lines and above the 5-day line at $590.27, with RSI at 35.2.
6aKey Price Levels Above and Below Current Price
Each colored bar matches the same-colored line on the chart; the percentage is the distance from the current price (green above · red below)
6bTechnical Indicators
6cOptions Market
Yahoo options values at collection time · calls are 64.8% of volume · max pain $585 for Nov 13 expiry and $720 for Nov 20
News & Schedule
After the Nov 2 Marvell deal the stock fell as much as 18.7% by Nov 5, then rebounded 5.7% on Nov 6 and 10.7% on Nov 9.
7aNews
11/2 Volume 15.34M shares
11/5 Volume 10.04M shares
11/9 Volume 6.04M shares
11/10 Volume —
9/29 Volume 6.04M shares
7bUpcoming Events
Macro
The US 10-year yield at 4.86% and WTI Dec futures at $86.85 have eased, and the VIX at 19.92 is lower, so some risk aversion has lifted.
Wall Street View
The 25-analyst average target of $1,066.59 is 78.9% above the close, but there were six cuts and one raise in eight days.
9aExternal Target Price Range
9bRecent Opinions by Firm
| Institutions | Opinion | Previous | Target Price | Change | vs. Close |
|---|---|---|---|---|---|
| Bernstein | Buy | 635 | 700 | Target raised | +17.4% |
| B. Riley Securities | Hold | 1,142 | 770 | Downgrade, target cut | +29.2% |
| TD Cowen | Hold | 820 | 685 | Target cut | +14.9% |
| Susquehanna | Buy | 1,100 | 950 | Target cut | +59.4% |
| Rosenblatt | Buy | 1,300 | 900 | Target cut | +51.0% |
Yahoo Finance: 25 analysts · average target $1,066.59 (high $1,425, low $635) · Buy 19, Hold 6, Sell 0 · table shows five changes from Nov 3 to Nov 10 · UBS cut its target from $960 to $686 on Nov 10 (kept Neutral, per news reports)[S4]
Risk Analysis
The two biggest risks are lower deal value if Marvell's stock falls and regulatory delay.
| Risk | Type | Likelihood | Impact | Dates to Watch |
|---|---|---|---|---|
| Lower deal value if Marvell's stock falls | Merger | High | High | Shareholder votes and regulatory review |
| Regulatory delay or block | Merger | Medium | High | Regulator announcements |
| Slowing AI data center customer capex | Earnings | Medium | High | February Q4 earnings |
| Quarterly free cash flow down 80.7% | Financial | Medium | Medium | February Q4 earnings |
| Volatility from being 47.8% below the 52-week high | Price | High | Medium | Nov 13 and Nov 20 options expiries |
| Share count up 27.7% from convertible conversions | Financial | Low | Medium | Next 10-Q |
Likelihood and impact rated High·Medium·Low · When it clears: When it resolves: Marvell and Lumentum shareholder votes and regulatory review (dates TBD) · Nov 13 and Nov 20 options expiries · Q4 2026 earnings in early February 2027
Checkpoints & Open Questions
The two key checks are the 4.5-share value of Marvell's stock and the shareholder vote and regulatory review schedule.
11aCheckpoints
11bOpen Questions
Sources & Data Dates
Numbers without a source are not published.
| ID | Type | Provider | Content | As-of Date |
|---|---|---|---|---|
| S1 | Price and indicators | Yahoo Finance | Close, moving averages, RSI, 52-week range, Supertrend, Bollinger | 2026.11.11 |
| S2 | Financials | Yahoo Finance quarterly and annual statements (through Q3 2026) | Quarterly revenue, earnings, cash flow, balance sheet, share count | 2026.11.11 |
| S3 | Earnings release | Lumentum fiscal Q1 2027 earnings release (https://investor.lumentum.com) | Revenue $1.26B, net income, non-GAAP EPS of $4.57, December-quarter guidance, June-quarter debt extinguishment loss | 2026.11.02 |
| S4 | Price targets and consensus | Yahoo Finance | Analyst rating mix, targets, rating changes | 2026.11.11 |
| S5 | Options | Yahoo Finance | Put/call ratio, volume by strike, max pain | 2026.11.11 |
| S6 | SEC filings | SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1633978/000162828026069615/lite-20260926.htm) | 10-Q (Nov 3, 90.68M shares), 8-K (Nov 2 merger agreement), multiple 425s | 2026.11.11 |
| S7 | Deal terms | Joint Marvell–Lumentum announcement (SEC 8-K press release https://www.sec.gov/Archives/edgar/data/0001633978/000119312526442758/d163169dex991.htm) | 4.5-share ratio, 23.9% premium, about 67%:33% ownership (fully diluted), closing target first half of 2028 | 2026.11.02 |
| S8 | Peer comparison | Yahoo Finance | P/E and P/S for five peers | 2026.11.11 |
| S9 | Insider trades | Yahoo Finance (Form 4 summary) | Three sales by WUPEN YUEN | 2026.11.11 |
| S10 | News reports | Headlines from TIKR, 24/7 Wall St., MT Newswires, Zacks, IBD | Nov 5–Nov 10 sector and price target (Bernstein, UBS) reports | 2026.11.10 |
Price as of the Nov 9, 2026 close (the last completed close; the US Nov 10 session was still open at the Nov 11 KST cutoff) · financials Q3 2026 (Yahoo Finance and company earnings release) · guidance per company release
※ Based on research team debate tally · of six issues, Bull wins 4 (earnings, valuation, cash, optical demand: 1 each), Bear wins 2 (Marvell deal is the key issue at weight 2, price target cuts 1), hold 0 → weighted Bull 4 vs Bear 3, a 1-vote gap, so HOLD